Dr. Westphal is co-founder and General Partner of Longwood Fund and has spent over 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed IPOs and created sustained market value of over $70 billion and have developed and received FDA approval for over 10 important drugs, including the first RNA medicines. These include: Momenta (NASDAQ: MNTA, acquired by J&J), Alnylam (NASDAQ: ALNY), Acceleron (NASDAQ: XLRN, acquired by Merck), Sirtris (NASDAQ: SIRT, acquired by GSK), Verastem (NASDAQ: VSTM), and TScan (NASDAQ: TCRX). Dr. Westphal was also co-founder of Alnara (acquired by Eli Lilly); co-founder/CEO of DEM Bio; co-founder/CEO of Immunitas; co-founder/Exec Chair of Solu; co-founder/Exec Chair of Newleos; co-founder of Pyxis (NASDAQ: PYXS); and co-founder of Concert (NASDAQ: CNCE, acquired by Sun Pharma). Dr. Westphal and Longwood partners have founded over 20 biotech companies, receiving FDA approval for over 20 important drugs, and created sustained market caps of over $190 billion. Dr. Westphal earned his M.D. from Harvard Medical School, his Ph.D. in genetics from Harvard University, and graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Innovation Organization (BIO), the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra. He is also a member of the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes, CNN's Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles.